Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 68Ga-OncoFAP in Solid Tumors
NCT05784597Phase 1Completed
- Sponsor
- Philogen
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ga-OncoFAP in breast cancer, colorectal cancer (CRC), esophageal cancer and 1 more (2 cohorts), sponsored by Philogen. Primary endpoints: Safety (Adverse Events) at 8 days, Dosimetry - Effective dose equivalent at Day 1 and 1 more. Started Apr 2023; status: completed.
02
Drugs
Ga-OncoFAP
03
Conditions
breast cancercolorectal cancer (CRC)esophageal cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05784597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784597.